NEW YORK (GenomeWeb News) – China Medical Technologies said today that its wholly owned subsidiary Beijing GP Medical Technologies and Gaoxin Da An Healthcare Investments are collaborating to bring molecular diagnostic technologies to the Chinese market.
Under the deal, GP Medical and Da An Health will co-market and promote GP Medical's molecular diagnostic products to Da An Health's customer base of hospitals. The two companies will also jointly develop new MDx products targeted to Da An Health's hospital customers.
Financial and other terms of the deal were not disclosed.
Based in Beijing, China Medical Technologies develops diagnostics. Its molecular diagnostic products include those using FISH and surface plasmon resonance technologies.
Da An Health provides clinical diagnostic testing services and has eight clinical testing centers serving thousands of hospitals in China.